In June 2012 the predecessor company of advanceCOR, Corimmun, was sold to Janssen-Cilag GmbH, Neuss, a subsidiary of Johnsen & Johnsen. 100 million USD were paid upfront and further milestone payments were agreed.
All non-COR-1 assets were transferred to advanceCOR and advanceCOR was founded 2012.
in March 2013 a phase II study with Revacept in 150 patients with carotid artery stenosis and recent stroke or TIA was started ( EudraCT Nr: 2011-001006-10)
In November 2017 a phase II study with Revacept in 332 patients with stable coronary artery disease was initiated by the German Heart Center in collaboration with the DZHK. (EudraCT NR 2015-000686-32)
In December 2017 scientific advice for preclinical and clinical development of a peptide for treatment of M. Basedow was held at the BfArm.
In September 2019 the last patient completed the Phase II study with Revacept in patients with carotid artery stenosis. Results have been evaluated by an independent data analysis group. Favourable results for a decrease in minor strokes determined by DWI- MRI and reduction of severe clinical events with no increase of bleeding complications were noted.
In March 2020 the phase II study with Revacept in patients with stable coronary artery disease has been completed. Data analysis is currently ongoing.